Melissa Beelen
Keine laufenden Positionen mehr
Karriereverlauf von Melissa Beelen
Ehemalige bekannte Positionen von Melissa Beelen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EPIZYME, INC. | Corporate Officer/Principal | 01.11.2015 | 01.03.2019 |
IQVIA HOLDINGS INC. | Corporate Officer/Principal | 01.08.2010 | 01.11.2015 |
GSK PLC | Corporate Officer/Principal | 01.01.1998 | 01.01.2010 |
ClinTrials Research, Inc.
ClinTrials Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Marvell Technology, Inc., ClinTrials Research, Inc. engages in clinical research organization. The company is based in Cary, NC. ClinTrials Research was acquired by Indigo Acquisition Corp on April 03, 2001 for $110.42 million. | Corporate Officer/Principal | 01.01.1994 | 01.01.1996 |
IN8BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2019 | - |
Ausbildung von Melissa Beelen
University of North Carolina System | Undergraduate Degree |
North Carolina State University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Vereinigtes Königreich | 2 |
Operativ
Corporate Officer/Principal | 4 |
Undergraduate Degree | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
IN8BIO, INC. | Health Technology |
IQVIA HOLDINGS INC. | Health Services |
GSK PLC | Health Technology |
Private Unternehmen | 2 |
---|---|
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
ClinTrials Research, Inc.
ClinTrials Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Marvell Technology, Inc., ClinTrials Research, Inc. engages in clinical research organization. The company is based in Cary, NC. ClinTrials Research was acquired by Indigo Acquisition Corp on April 03, 2001 for $110.42 million. | Commercial Services |
- Börse
- Insiders
- Melissa Beelen
- Erfahrung